Analysts Set Expectations for RGLS Q1 Earnings

Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) - Equities research analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for Regulus Therapeutics in a note issued to investors on Wednesday, April 30th. Leerink Partnrs analyst J. Schwartz expects that the biopharmaceutical company will post earnings of ($0.23) per share for the quarter. Leerink Partnrs has a "Hold" rating on the stock. The consensus estimate for Regulus Therapeutics' current full-year earnings is ($0.88) per share. Leerink Partnrs also issued estimates for Regulus Therapeutics' Q2 2025 earnings at ($0.27) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.34) EPS and FY2026 earnings at ($1.06) EPS.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last announced its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.20) EPS for the quarter, hitting the consensus estimate of ($0.20). During the same period last year, the business earned ($0.40) EPS.

Other research analysts have also issued reports about the company. Leerink Partners reissued a "market perform" rating and issued a $7.00 price objective on shares of Regulus Therapeutics in a research report on Wednesday, April 30th. Wells Fargo & Company reiterated an "equal weight" rating and set a $9.00 price objective on shares of Regulus Therapeutics in a research note on Thursday, May 1st. Canaccord Genuity Group restated a "hold" rating and issued a $11.00 target price (down from $28.00) on shares of Regulus Therapeutics in a research note on Wednesday, April 30th. HC Wainwright reaffirmed a "buy" rating and set a $10.00 price target on shares of Regulus Therapeutics in a research note on Friday, March 14th. Finally, Jones Trading restated a "hold" rating and set a $7.00 price objective (down from $8.00) on shares of Regulus Therapeutics in a report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat.com, Regulus Therapeutics presently has a consensus rating of "Hold" and an average price target of $8.50.

Regulus Therapeutics Price Performance

Shares of Regulus Therapeutics stock remained flat at $7.85 during trading hours on Monday. 474,183 shares of the stock traded hands, compared to its average volume of 871,880. The firm has a market cap of $520.01 million, a P/E ratio of -7.34 and a beta of 0.49. The firm has a fifty day moving average price of $2.50 and a two-hundred day moving average price of $1.79. Regulus Therapeutics has a 52 week low of $0.83 and a 52 week high of $8.20.

Hedge Funds Weigh In On Regulus Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Federated Hermes Inc. boosted its position in Regulus Therapeutics by 23.1% during the 1st quarter. Federated Hermes Inc. now owns 15,819,863 shares of the biopharmaceutical company's stock worth $27,685,000 after acquiring an additional 2,967,209 shares during the period. Tyche Wealth Partners LLC increased its stake in Regulus Therapeutics by 14.6% during the 1st quarter. Tyche Wealth Partners LLC now owns 121,589 shares of the biopharmaceutical company's stock valued at $213,000 after buying an additional 15,500 shares during the period. Oppenheimer & Co. Inc. acquired a new stake in shares of Regulus Therapeutics in the 1st quarter worth approximately $96,000. Velan Capital Investment Management LP acquired a new position in shares of Regulus Therapeutics during the fourth quarter valued at approximately $111,000. Finally, Octagon Capital Advisors LP lifted its position in Regulus Therapeutics by 13.7% in the fourth quarter. Octagon Capital Advisors LP now owns 4,848,802 shares of the biopharmaceutical company's stock worth $7,661,000 after purchasing an additional 585,101 shares during the period. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.